About 4,000 volunteers registered themselves as part of a study being conducted on a vaccine against the emerging coronavirus (Covid-19) at the university hospital in Tubingen, Germany.
Study director Peter Kremsner told Deutsche Presse-Agentur dpa: "It is a situation of real luxury, unlike usual clinical trials ... we usually find it difficult to reach enough people to be test subjects."
A clinical study began at the university clinic in mid-June to test the vaccine developed by the "Cure Vak" company for biological medicines in the town of Tübingen.
Since then, about 50 people have taken the drug. According to Kremsner, there have been no sudden side effects yet.
Everything was fine so far, Kremsner said, adding that the study did not reveal any disturbing results.